BACKGROUND: Autoantibodies to cardiac troponins (TnAAbs) could negatively affect cardiac troponin I (cTnI) measurements by TnAAbs-sensitive immunoassays. We investigated the epitope specificity of TnAAbs and its influence on cTnI immunodetection in patients with acute myocardial infarction (AMI).
The troponin complex is responsible for the regulation of skeletal and cardiac muscle contractions (1 ) . The complex consists of troponin I (TnI), 5 troponin T (TnT) and troponin C (TnC). TnI and TnT are present in the heart as specific cardiac isoforms: cardiac TnI (cTnI) and cardiac TnT (cTnT). On acute myocardial infarction (AMI), cTnI and cTnT are released from necrotic tissue into the bloodstream and their measurements are widely used for AMI diagnosis (2 ) . The blood of some AMI patients contains an interfering factor that negatively influences the immunodetection of troponin complex components leading to underestimation of real protein concentrations (3 ) . This interfering factor was identified as anti-cardiac troponin autoantibodies (TnAAbs) (4 -9 ) . TnAAbs were found in the blood of about 8% of healthy individuals, so the detection of cTnI spiked in the form of ternary cardiac troponin complex (I-T-C) was impaired in the blood samples of these persons and cTnI recovery by certain assays appeared to be Ͻ10% (3, 4, 7, 8, 10 ) . The negative interference of TnAAbs with the cTnI measurements was observed mainly for immunoassays that utilize at least 1 antibody that is specific to the midfragment of cTnI [30 -110 aar (amino acid residues)] (10, 11 ) . TnAAbs that hinder the detection of cTnT have also been described (6, 12, 13 ) .
Although it is believed that cTnI in the blood of AMI patients is mainly present in the form of binary cardiac troponin complex (I-C) (14, 15 ) , most studies have used I-T-C to demonstrate the negative interference of TnAAbs with the cTnI assays (4, 7, 10 ) .
Our aim was to compare the influence of TnAAbs on the measurements of 4 different forms of cardiac troponins: I-T-C, I-C, cTnI, and cTnT, by different cTnIand cTnT-specific assays.
Materials and Methods
Various forms of troponins were evaluated, including native human I-T-C, native human cTnI, recombinant human cTnT, and I-C (where the complex was formed by combining cTnI and TnC). I-C complex completeness was controlled in immunoassays using monoclonal antibodies (mAbs) specific only to free cTnI or only to I-C. mAbs specific to cTnI (epitope) included TnI19C7 (41-49), TnI560 (83-93), TnI625 (169 -178), and TnIMF4 (190 -196 
SANDWICH IMMUNOFLUORESCENT ASSAYS
All samples were analyzed by sandwich 2-step immunofluorescent assays as described in (16 ) (see the Data Supplement that accompanies the online version of this article at http://www.clinchem.org/content/vol63/issue1).
TROPONIN RECOVERY STUDIES
I-T-C, I-C, cTnI, or cTnT were spiked into the plasma samples of healthy individuals or into buffer A (20 mmol/L Tris-HCl, pH 7.5, containing 150 mmol/L KCl, 5 mmol/L CaCl 2 , 75 g/L BSA, 5 g/L bovine IgG, and 0.15 g/L NaN 3 ) (see online Data Supplement) to a final concentration of 50 g/L, incubated on ice for 10 min and measured by different immunoassays.
The recovery was calculated as the ratio of the signal obtained from the antigen spiked into the plasma sample to the signal of the antigen spiked into buffer A and was expressed as a percentage.
To study the recovery of cTnI present in the blood of AMI patients, plasma samples from AMI patients were mixed 1:1 with TnAAbs-containing plasma. Each patient sample for each time point was mixed with 4 individual TnAAbs-containing plasma samples to be sure that the inhibition effect was not just a property of one particular TnAAbs-containing sample. The ratios of the signals obtained by measuring samples of AMI patients mixed with TnAAbs-containing samples to the signals obtained by measuring the same AMI samples mixed with the reference TnAAbs-free plasma sample [for this sample recovery of cTnI in the form of I-T-C in TnI19C7-TnI560 assay was 77% and the absence of TnAAbs was confirmed by gel filtration (GF)] were expressed as percentages and were assumed to be a recovery.
ISOLATION OF THE IMMUNOGLOBULIN FRACTION FROM

PLASMA SAMPLES
The extraction of the IgG fraction from plasma was performed on Protein G Sepharose according to a standard procedure (see online Data Supplement).
GEL-FILTRATION PROCEDURE
The gel-filtration studies (GF) were performed using an AKTA pure chromatography system (GE Healthcare) on a HiLoad Superdex 200 PG 16/60 column (GE Healthcare) (see online Data Supplement).
STATISTICAL ANALYSIS
Statistical analysis was performed using Microcal Origin software (version 7.5). The Mann-Whitney U-test was used to calculate the significance of differences between groups. Correlations between groups were assessed by Spearman rank order correlation. A value of P Ͻ0.05 was considered statistically significant in all analyses.
Results
IDENTIFICATION OF PLASMA SAMPLES CONTAINING TnAABs
One hundred and ninety-one plasma samples from healthy donors were analyzed to find samples with low recovery of I-T-C. All samples were spiked with I-T-C and analyzed by the TnI19C7-TnI560 assay, which uses antibodies to cTnI epitopes most sensitive to the presence of TnAAbs, and the TnI625-TnIMF4 assay, which is insensitive to TnAAbs (4, 11, 17 ) .
Twenty-one plasma samples with the cTnI recovery Ͻ35% and plasma samples with high cTnI recovery (51%, 77%, and 84%) in the TnI19C7-TnI560 assay were analyzed by GF. All samples were spiked with 100 g/L of I-T-C and after protein separation the immunological activity of cTnI in the fractions was detected by the TnAAbs-insensitive TnI625-TnIMF4 assay. The retention volumes for the I-T-C peak in 12 samples shifted to the area of higher molecular weight proteins as compared with I-T-C peak in buffer, suggesting the formation of high molecular weight complexes (presumably immune complexes) of plasma proteins with I-T-C in these samples. At the same time, for all other tested plasma samples there were no shifts of the immunoreactivity peak as compared with I-T-C in buffer ( Fig. 1 ).
In these 12 (6%) plasma samples, the recovery of the spiked I-T-C measured by the TnAAbs-sensitive TnI19C7-TnI560 assay was 1.9%-21.3% (mean, 10.3%), suggesting that these plasma samples contained TnAAbs. For all other plasma samples (n ϭ 179), the recovery ranged 30.8%-83.8% (mean, 47.4%). Relatively low recovery for spiked I-T-C in TnAAbs-free plasma samples measured by the TnAAbs-sensitive TnI19C7-TnI560 assay was also demonstrated by Eriksson et al. (3 ) . The recoveries measured by the TnAAbs-insensitive TnI625-TnIMF4 assay for the 12 TnAAbs-containing plasma samples ranged from 58.3% to 80.5% (mean, 73.2%) and 63.5% to 129.8% (mean, 95.0%) for all other plasma samples.
To confirm that a decrease in I-T-C recovery measured by the TnAAbs-sensitive TnI19C7-TnI560 immunoassay in the 12 selected samples was associated with autoantibodies, we isolated the IgG fractions from 3 plasma samples with low cTnI recoveries (1.9%, 2.5%, and 3.1%) and from 3 plasma samples with high recoveries by chromatography on Protein G Sepharose. I-T-C was spiked into the flow-through and eluate fractions to a final concentration of 50 g/L. The immunoreactivity was analyzed by the TnI19C7-TnI560 immunoassay.
The I-T-C recoveries in the eluted IgG fractions from low-recovery plasma samples were 13.0%-25.1% (mean, 17.8%) vs 80.3%-91.1% (mean, 86.5%) for high-recovery plasma samples. The recoveries in the flow-through fractions from low-and high-recovery plasma samples did not differ significantly: range 41.2%-58.1% (mean, 49.8%) vs 44.3%-68.8% (mean, 57.0%), respectively.
GF was also performed on flow-throughs and eluates of plasma samples with low and high cTnI recoveries passed through the protein G column. The shift of the I-T-C peak towards the high molecular weight area was only found for eluates but not for flow-throughs.
Thus we assume that the significant decrease in I-T-C recovery measured by the TnI19C7-TnI560 assay and the shift of I-T-C immunoreactivity peak in GF studies in some plasma samples are related to the binding of I-T-C to the specific autoantibodies fraction.
We suggest that such a shift of I-T-C immunoreactivity in GF studies could be used as a criterion for the presence of TnAAbs in the samples considered together with the testing of the I-T-C recovery in the TnI19C7-TnI560 assay. A relatively low mean I-T-C recovery (47.4%) in TnAAbs-free plasma samples (n ϭ 179) was not associated with autoantibodies and might be explained by negative matrix effects of the individual blood samples on the TnI19C7-TnI560 assay.
We also compared the inhibition of the cTnI detection in serum samples, and citrate and heparin plasma samples from the same donors having TnAAbs in their blood and found the same effect on the cTnI detection in the TnI19C7-TnI560 assay (data not shown).
EFFECT OF TnAABs ON THE IMMUNODETECTION OF FREE cTnI AND cTnI AS A PART OF THE I-C OR I-T-C COMPLEX
Although it is considered that cTnI in blood of AMI patients is present mainly in the form of I-C complex, we compared the influence of TnAAbs on the immunodetection of cTnI in the form of I-C and I-T-C and also in the free form by the TnAAbs-sensitive TnI19C7-TnI560 assay.
As mentioned above, the recoveries of I-T-C spiked into 12 TnAAbs-containing plasma samples ranged from 1.9% to 21.3% (mean, 10.3%) and were significantly lower (P Ͻ 0.05) than the 30.8%-83.8% (mean, 47.4%) recoveries observed in the TnAAbs-free plasma samples (control group, n ϭ 179). The I-C recoveries were 52.1%-97.1% (mean, 71.0%) vs 54.9%-96.9% (mean, 76.6%) and cTnI recoveries were 66.3%-125.7% (mean, 96.5%) vs 57.5%-145.7% (mean, 96.2%). Differences for recoveries of I-C or cTnI spiked into TnAAbs-containing vs TnAAbs-free samples were not statistically significant (Fig. 2) .
Our results demonstrate that the presence of cTnT in I-T-C is necessary for the inhibitory effect of TnAAbs on cTnI measurements by the TnAAbssensitive immunoassay.
We suggest that these autoantibodies might be either specific to cTnT and sterically hinder cTnI epitopes in I-T-C, or they might interact with the conformational epitopes that are formed by cTnI and cTnT polypeptide chains in I-T-C.
EFFECT OF TnAABs ON THE cTnT IMMUNODETECTION
To verify these suggestions, we determined whether the detection of cTnT was also negatively affected by TnAAbs. Absent published data describing epitopes for cTnT-specific autoantibodies, we determined the epitopes on the cTnT molecule that could be affected by TnAAbs. For this purpose we used a "mixed sandwich" assay approach in which TnAAbs-insensitive anti-cTnI mAb TnI625 was used as a capture antibody and 11 anti-cTnT mAbs specific for epitopes covering almost the entire cTnT sequence were used as detection antibodies. We did not test the 2-41 aar fragment of cTnT owing to a lack of specific mAbs, and did not use antibodies specific to the 242-275 fragment as such mAbs do not recognize cTnT in I-T-C.
We found that the recoveries of cTnT spiked in the form of I-T-C into TnAAbs-containing plasma samples (n ϭ 12) were a bit lower for almost all assays compared with 12 TnAAbs-free samples randomly selected from the 179 control samples, but the most prominent decrease of cTnT recovery was observed for the TnI625-TnT7E7 assay: 3.4%-49.4% (mean, 24.9%) vs 65.8%-128.5% (mean, 88.8%), respectively ( Fig. 3 ). We suggested that an epitope of mAb TnT7E7 is predominantly affected by TnAAbs. All the used assays that included mAb TnT7E7 were sensitive to TnAAbs (data not shown).
To determine whether TnAAbs recognize free cTnT or cTnT as a part of I-T-C only (as shown above for cTnI), cTnT and I-T-C were spiked into TnAAbscontaining plasma samples (n ϭ 12) and TnAAbs-free samples (n ϭ 12), and cTnT was measured by TnAAbssensitive TnT105-TnT7E7 and TnAAbs-insensitive TnT105-TnT9 assays.
The I-T-C recovery measured by the TnAAbssensitive TnT105-TnT7E7 assay in the TnAAbscontaining samples ranged from 4.1%-32.4% (mean, 15.2%) and was significantly lower (P Ͻ 0.05) than in the TnAAbs-free samples that ranged from 50.1%-77.8% (mean, 66.3%). No significant difference (P ϭ 0.3) was observed when free cTnT was spiked into the same samples: 60.4%-83.6% (mean, 72.8%) vs 62.1%-68.6% (mean, 65.3%).
No significant differences were found in the TnAAbs-insensitive assay TnT105-TnT9 between the recoveries of either free cTnT or cTnT as a part of I-T-C in TnAAbs-containing and TnAAbs-free plasma samples.
These data suggest that TnAAbs negatively affect only the immunodetection of cTnT incorporated into I-T-C.
GEL-FILTRATION STUDIES OF TROPONINS SPIKED INTO THE
TnAABs-CONTAINING PLASMA SAMPLES
To confirm that TnAAbs only interact with I-T-C and do not recognize I-C or free cTnT, plasma samples spiked with different troponin forms were analyzed using GF. I-C, cTnT, or I-T-C (as a control) at a concentration of 100 g/L were spiked into TnAAbs-containing plasma samples (n ϭ 12) or into TnAAbs-free plasma samples (n ϭ 6). After protein separation by GF, the immunoactivity of cTnI and cTnT in the fractions was detected by the TnI625-TnIMF4 and TnT9 -TnT1A11 TnAAbs-insensitive assays (Fig. 4) .
The retention volumes for I-C and cTnT peaks in TnAAbs-containing samples were the same as in the TnAAbs-free plasma samples and coincided with the peaks of I-C and cTnT gel-filtered in buffer. As described in the section Identification of Plasma Samples Containing TnAABs, the retention volumes for the peak of I-T-C in TnAAbs-containing samples shifted to the area of higher molecular weight proteins. It was concluded that TnAAbs form a high molecular weight complex only with I-T-C and not with I-C or cTnT. The I-T-C complex, I-C complex, and free cTnI were spiked into the TnAAbs-free (n = 179) or TnAAbs-containing plasma samples (n = 12) at a concentration of 50 μg/L and were measured by the TnI19C7-TnI560 immunoassay. The boxes indicate the 25th-75th percentiles; whiskers represent minimum and maximum recoveries; inner unshaded boxes indicate the mean recoveries; and lines, the median values.
CORRELATION BETWEEN THE cTnI AND cTnT RECOVERIES
To demonstrate the relationship between the inhibition of cTnI and cTnT immunodetection, we calculated the Spearman correlation between TnAAbs effects on the recovery of cTnI and cTnT spiked in the form of I-T-C into TnAAbs-containing plasma samples and measured by the TnAAbs-sensitive assays TnI19C7-TnI560 and TnT105-TnT7E7 (see Fig. 1 in the online Data Supplement).
The Spearman correlation coefficient for the recovery of cTnI vs cTnT spiked into the TnAAbs-containing samples in the form of I-T-C was r ϭ 0.97 which demonstrated the strong correlation between the negative interference of TnAAbs with cTnI and with cTnT detection.
These results suggest that some epitopes on the surface of the cTnI and cTnT molecules in I-T-C are simultaneously blocked by the same TnAAbs.
INFLUENCE OF TnAABs ON THE DETECTION OF
ENDOGENOUS cTnI IN PLASMA SAMPLES OF AMI PATIENTS
To study the influence of TnAAbs on the detection of troponins in the plasma samples of AMI patients, we measured cTnI immunoreactivity in AMI plasma samples mixed with TnAAbs-containing plasma samples. Thirty-five plasma samples with cTnI concentrations of 2.7-35.1 g/L collected within 4 -36 h following the onset of chest pain from 15 AMI patients were mixed 1:1 with 4 different TnAAbs-containing plasma samples or with the reference TnAAbs-free plasma sample. The cTnI recovery was measured by TnAAbs-sensitive TnI19C7-TnI560 and TnAAbs-insensitive TnI625-TnIMF4 assays.
In this experiment, the recovery was calculated as the percentage of the signals in the AMI samples mixed with TnAAbs-containing samples to the signals in the AMI sample mixed with the reference TnAAbs-free plasma sample. For comparison, I-T-C and I-C were used instead of AMI plasma samples at a concentration of 50 g/L.
The recoveries of cTnI measured by the TnAAbssensitive TnI19C7-TnI560 immunoassay in AMI samples that were mixed with TnAAbs-containing samples were 22.3%-101.1% (mean, 61.4%). These recoveries on the mixed samples were considerably higher than the recoveries of the standard I-T-C and slightly lower than the standard I-C in the same TnAAbs-containing samples: 3.2%-17.8% (mean, 10.4%) and 69.8%-96.3% (mean, 85.7%), respectively. The recoveries of cTnI measured by the TnAAbs-insensitive TnI625-TnIMF4 immunoassay in AMI samples mixed with TnAAbscontaining samples were 54.0%-98.0% (mean, 81.2%), The I-T-C complex was spiked into the TnAAbs-free (n = 12) and TnAAbs-containing plasma samples (n = 12), and measured by immunoassays that utilize TnI625 as the capture mAb and different anti-cTnT mAbs as detection mAbs. Anti-cTnT mAbs were specific to different epitopes on the cTnT molecule. Epitopes of the anti-cTnT mAbs are shown in brackets. The whiskers represent SDs of the mean values. and for the control I-T-C and I-C they were 64.4%-85.1% (mean, 75.9%) and 90.3%-107.2% (mean, 98.0%), respectively (Fig. 5 ).
In the original AMI samples, the concentrations of endogenous I-T-C measured by the TnAAbs-sensitive TnI625-TnT7E7 "mixed" assay were 36.6%-82.5% of the total cTnI. When these AMI samples were mixed with TnAAbs-containing samples, the concentrations of I-T-C in them were determined as 0.9%-31% (mean, 7.4%) of the initial values. Since only the mea-surement of I-T-C is inhibited by TnAAbs, these data prove the presence of I-T-C, besides, I-C commonly believed to be present in the plasma samples of AMI patients.
When serial plasma samples of AMI patients (n ϭ 6) collected 4 -9, 10 -19, and 22-36 h following the onset of symptoms were mixed with 4 different TnAAbscontaining plasma samples, it was found that the negative influence of TnAAbs on the cTnI recoveries measured by TnAAbs-sensitive TnI19C7-TnI560 assay was most pronounced during the first hours following the onset of symptoms and became weaker at later times. The recoveries of cTnI in samples collected at 4 -9, 10 -19, and 22-36 h following AMI were 22.3%-44.9% (mean, 38.1%), 32.1%-74.1% (mean, 59.3%), and 50.3%-101.2% (mean, 78.0%), respectively (Fig. 6 ).
We suggest that early AMI blood samples contain a mixture of I-T-C and I-C with the ratio gradually changing with the progression of the disease in favor of I-C. 
Discussion
The selection of antibodies for cTnI immunoassays is a difficult task. The presence of autoantibodies that could negatively influence cTnI measurements in the blood of patients should be considered by clinicians and researchers, who develop immunoassays.
We investigated how TnAAbs influence the recognition of cTnI present in a sample in different molecular forms (cTnI, I-C, and I-T-C) by using assays that were shown to be sensitive to TnAAbs.
In this work, we selected TnAAbs-positive samples using TnI19C7-TnI560 assay because, on the one hand, TnI19C7 and TnI560 mAbs were reported to be most sensitive to the presence of TnAAbs (4, 10, 11 ) and, on the other hand, epitopes of cTnI that are recognized by these mAbs are widely used in the commercial assays (18 ) .
However, autoantibodies to other cTnI epitopes (4, 11 ) and to free cTnI (9 ) and cTnT (12, 13 ) were also reported. So TnAAbs in the population can differ from the TnAAbs characterized in this study, and the limitation of this study is that only a portion of all autoantibodies to cardiac troponins was analyzed.
By using GF, we confirmed the hypothesis that these TnAAbs only interact with I-T-C but not with I-C or free cTnT molecules. We did not use free cTnI in the GF experiments because of the low recovery of the eluted protein. The data in Figs. 1 and 4 demonstrate that only in the case of I-T-C was there a shift of the immunoreactivity peaks for TnAAbs-containing samples to higher molecular weights, confirming the formation of the immune complexes between the I-T-C and TnAAbs. We suggest that such GF studies could be used (together with other approaches) as a method for the detection of the presence of TnAAbs in samples. In the current study, we used this approach to discriminate TnAAbs-containing samples from the TnAAbs-free samples displaying relatively low I-T-C recovery in the TnI19C7-TnI560 immunoassay.
The results of our experiments revealed that among 3 tested cTnI forms, it was only the detection of I-T-C that was significantly affected by TnAAbs. In contrast, the measurement of I-C, which is considered to be the most interesting for clinicians, was less sensitive to the presence of TnAAbs.
Our data also demonstrated that TnAAbs that interfere with the TnI19C7-TnI560 assay also interfere with cTnT assays that use the anti-cTnT mAb specific to the 223-242 region.
Similarly to cTnI, TnAAbs only influence the cTnT measurements when cTnT is present in the form of I-T-C and have no effect on the measurement of free cTnT.
According to the quaternary structure of I-T-C, the central region comprising 42-136 aar of cTnI and a fragment 203-271 of the cTnT molecule form the so-called "IT-arm" (19 ) . Based on the results of our experiments, we suggest that TnAAbs interfering with TnI19C7-TnI560 immunoassay are not specific to the individual cTnI or cTnT molecules as was considered previously (20 -22 ) , but are instead specific to the conformational epitopes that include both the cTnI and cTnT polypeptide chains that form the IT-arm.
Considering that cTnI in the blood samples of patients is believed to be present as I-C and measurements of I-C are almost completely unaffected by TnAAbs (as was shown in the current study), one can suggest that TnAAbs should not affect the detection of cTnI in the samples of patients. However, we found some decrease in the amount of the detectable cTnI when AMI plasma samples were mixed with TnAAbs-containing plasma samples. The negative influence of TnAAbs on the detection of cTnI in the plasma samples of AMI patients decreased with time and became almost negligible in the samples collected 22-36 h following the onset of the chest pain. The data obtained suggest that in the early samples of AMI patients, cTnI is present as a mixture of I-C and I-T-C, where only I-T-C detection is inhib- ited by TnAAbs. Later I-C becomes the predominant form of cTnI and is not affected by TnAAbs.
Considering that the most interesting time window from the clinical point of view is 1-3 h after the onset of chest pain, additional studies of cTnI forms released into the bloodstream of patients as well as additional studies of the negative influence of TnAAbs on the cTnI measurements in the early samples are needed.
Conclusion
In this study, we demonstrated that certain TnAAbs hindering the cTnI detection by the mAbs to the central part of cTnI are specific to the conformational epitopes formed by polypeptide chains of cTnI and cTnT that are closely located in the IT-arm of I-T-C. We also suggest that cTnI in the early AMI samples is present as a mixture of I-C and I-T-C complexes. As measurements of I-T-C are negatively affected by TnAAbs, the real concentration of cTnI in the early samples of AMI patients measured by certain assays could be underestimated in 5%-10% of AMI patients. The effect of TnAAbs on cTnI detection is less in samples collected 10 -20 h following the AMI onset possibly owing to the fact that I-C becomes the predominant cTnI form as the disease progresses.
